Pacific Biosciences of California, Inc. (PACB)
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.66, moving 1.19% from the previous trading session.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) closed at $1.68 in the latest trading session, marking a -2.89% move from the prior day.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.31, moving 2.96% from the previous trading session.
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.
Pacific Biosciences of California Q1 Earnings Call Highlights
Pacific Biosciences of California NASDAQ: PACB reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument performance amid ongoing pressure in academic and government funding, particularly in the U.S.
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down
PacBio beats Q1 earnings estimates as consumables growth and cost cuts offset flat revenue and a weaker gross margin.
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
PACB heads into Q1 earnings with strong consumables momentum, but muted academic demand and macro pressures cloud near-term visibility.
